Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Circulating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating Cells
Conferences  \  Circulating Biomarkers World Congress 2017  \  Circulating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating Cells  \  Agenda  \  Shannon Stott
RegisterLogin

Shannon Stott's Biography


Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School

The Stott laboratory is comprised of bioengineers and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, we are interested in using microfluidics and imaging technologies to create tools that increase understanding of cancer biology and of the metastatic process. In collaboration with the Toner, Haber and Maheswaran laboratories, we have developed a microfluidic device that can isolate extraordinary rare circulating tumor cells (CTCs) from the blood of cancer patients. We are striving to employ new imaging modalities to extract as much information as possible from these rare cells while pushing the technology further for early cancer detection. Ultimately, we hope that by working in close partnership with the molecular and cell biologist at the Mass General Cancer Center, we can create new tools that directly impact patient care.

Shannon Stott Image

Microfluidics for the Interrogation of Circulating Biomarkers in Glioblastoma Patients

Monday, 20 March 2017 at 17:30

Add to Calendar ▼2017-03-20 17:30:002017-03-20 18:30:00Europe/LondonMicrofluidics for the Interrogation of Circulating Biomarkers in Glioblastoma PatientsSELECTBIOenquiries@selectbiosciences.com

Clinically, there is a dire need to diagnose and monitor brain tumor recurrence and to detect mutations in real time to guide patient treatment. A blood-based ‘liquid biopsy’ that captures and analyzes both circulating tumor cells (CTCs) and extracellular vesicles (EVs) would be an ideal approach to better predict tumor response in glioblastoma patients without the need for highly invasive brain surgery. Through these blood-on-a-chip assays, we aim to gain a better understanding of when these important tumor derived CTCs and extracellular vesicles are released and how we can exploit their molecular content to better guide patient treatment. Working in partnership with Dr. Brian Nahed at MGH, we have used our microfluidic technologies to isolate CTCs and EVs from the blood of patients with advanced glioblastoma multiforme. In this talk, data will be presented on our technological approach as well as our effort to interrogate their molecular content using next generation RNA sequencing. Through the microfluidic isolation of blood based biomarkers from patients, our goal is to obtain complementary data to the current standard of care to help better guide treatment.

Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating CellsSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors
Related Conferences
Lab-on-a-Chip, Microfluidics, & Organ-on-a-Chip Asia 2024
Location: Tokyo, Japan
Date: 07/11/2024 - 08/11/2024


Organoids and Spheroids Europe 2024
Location: Rotterdam, The Netherlands
Date: 24/06/2024 - 25/06/2024


Organoids, Spheroids & Organs-on-Chips 2024
Location: Laguna Hills, California
Date: 18/11/2024 - 20/11/2024